市传阿斯利康大削今年首季向欧盟供应新冠疫苗数量六成
《路透》引述消息报道,英国药厂阿斯利康已通知欧盟,今年首季将交付3,100万剂新冠疫苗,较原来预计的约8,000万剂削减六成,药厂要到今年第二季才能完成供应8,000万剂。消息亦指.,阿斯利康将於2月15日起交付疫苗。
报道指,药厂向欧盟解释,削减交付量是因为业务夥伴Novasep在比利时的疫苗厂出现生产问题。
阿斯利康药厂发言人向《路透》证实削减交付量,但未披露削减数字。欧盟将旒於周五(29日)批准使用阿斯利康的疫苗。欧盟已签约订购最少3亿剂疫苗,并有选择权采购额外1亿剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.